FutureGen pairs two CLDN18.2 antibodies in new China -tumor trial
The Phase I/II combination of FG-M108 and FG-B901 tests whether stacking two CLDN18.2-targeted antibodies adds benefit beyond FutureGen's own single-agent program already in Phase 3.
Executive Summary
- FutureGen Biopharmaceutical registered a new early-phase combination trial testing its CLDN18.2-targeted antibody alongside a second in-house antibody in advanced tumors.
- The combination sits alongside FutureGen's own single-agent program for the same target, which has already advanced into registrational testing, giving the company an internal benchmark for whether pairing the two adds benefit.
- CLDN18.2 is one of the more actively pursued targets in gastrointestinal and other -tumor oncology, with direct comparators spanning monoclonal antibodies, antibody-drug conjugates, and cell therapies at every phase from Phase 1 through Phase 3.
- Because the study has not yet started recruiting and carries no posted results, its near-term value is establishing feasibility and initial activity signal for the combination, not a decision-grade efficacy readout.
The trial
The study, registered as NCT07704866, will enroll an anticipated 120 patients with locally advanced or metastatic CLDN18.2-positive tumors who have failed or cannot tolerate standard therapy, in second-line-or-later treatment. Eligibility requires central-lab confirmation of CLDN18.2 positivity, defined as membrane staining in at least 10% of tumor cells. The trial is set to start July 30, 2026 in China, with a primary completion date of August 31, 2028 and a study completion date of February 28, 2029. It is listed as not yet recruiting and is not designated registrational. NCT07704866A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid TumorsNCT07704866
What it will test
The trial's primary outcome measures are disease control rate and objective response rate by RECIST 1.1, tracked through 24 months, alongside safety assessed by adverse-event incidence. Secondary measures include duration of response, progression-free and overall survival, and pharmacokinetic parameters (half-life, Cmax, Tmax) for both FG-B901 and FG-M108. That combination of tumor-response and pharmacokinetic endpoints is consistent with an early-phase study designed to characterize the combination's activity and behavior in the body before any registrational commitment. NCT07704866A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid TumorsNCT07704866
The sponsor's own precedent
FutureGen already sponsors a Phase 3 trial of FG-M108 as a monotherapy in pancreatic cancer, targeting the same CLDN18.2 antigen, with a primary completion date of June 2030 and an overall survival primary endpoint. That program gives the sponsor an internal single-agent reference against which any activity signal from the FG-M108/FG-B901 combination in this new trial can eventually be compared, even though the two studies enroll different tumor types and are not designed as a head-to-head comparison. NCT07383922
The competitive field
CLDN18.2 is a mechanism with an active and mechanistically diverse competitive field: direct comparators include Astellas Pharma's ASP2138 and Sichuan Baili Pharmaceutical's BL-M05D1, both monoclonal antibodies in Phase 3 gastric cancer trials, alongside Innovent Biologics' IBI343 and Qilu Pharmaceutical's QLS31905 in Phase 3 pancreatic cancer, and cell-therapy and antibody-drug-conjugate programs from Suzhou Immunofoco Biotechnology and Suzhou Suncadia Biopharmaceuticals. Modality is spread across monoclonal antibodies, ADCs, bispecifics, and CAR-T or CAR-NK cell therapies, with 39 industry trials in Phase 1 and 34 in Phase 2 targeting CLDN18.2. Given that breadth, a combination arm from an existing single-agent developer distinguishes itself only if it demonstrates disease control or response beyond what monotherapy CLDN18.2 antibodies have shown in comparable -tumor populations; the trial's design does not yet supply that comparison.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.